Table 3 shows also the percentages of patients treated with endocrine therapy alone (started after surgery) or with endocrine therapy administered after chemotherapy (with or without anti-HER2 agent), according to breast cancer phenotypic subgroup. This evidence concerns the gene ERBB2 and breast cancer.